Avaleht/Aktsiad/PMVP

PMVP

USD

PMV Pharmaceuticals Inc. Common Stock

$1.340-0.040 (-2.899%)

Reaalajas hind

Healthcare

Biotehnoloogia

Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad

Ettevõtte fundamentaalnäitajad

Kauplemisstatistika

Turunäitajad

Avatud

$1.380

Kõrge

$1.430

Madal

$1.320

Maht

0.37M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

71.0M

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

1.26M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $0.81Praegune $1.340Kõrge $1.84

Seotud uudised

24. okt 2025 · 15:39

GlobeNewswire

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast,

Vaata rohkem

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

13. okt 2025 · 20:01

GlobeNewswire

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C

Vaata rohkem